Beactica Therapeutics Overview

  • Founded
  • 2006
Founded
  • Status
  • Private
  • Employees
  • 16
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $294K
Latest Deal Amount
  • Investors
  • 9

Beactica Therapeutics General Information

Description

Developer of a drug discovery platform designed to facilitate the treatment of glioblastoma and other cancers. The company's platform offers protein-based therapeutics that regulate the expression of disease-associated proteins in order to change the chromatin configuration that governs the regulation of DNA transcription and improve the immune system's ability to fight cancer, enabling medical practitioners to treat patients with cancer with improved efficiency and lower risks.

Contact Information

Website
www.beactica.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Virdings allé 2
  • 754 50 Uppsala
  • Sweden
+46 018-56 00 00

Beactica Therapeutics Timeline

2019202020212022
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Beactica Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Grant 18-Jun-2019 $294K Completed Pre-Clinical Trials
7. Later Stage VC 04-Jun-2019 Completed Pre-Clinical Trials
6. Grant 23-Mar-2018 000.00 Completed Pre-Clinical Trials
5. Later Stage VC 15-Dec-2014 Completed Pre-Clinical Trials
4. Accelerator/Incubator Completed Pre-Clinical Trials
3. Grant 20-Nov-2014 00000 Completed Pre-Clinical Trials
2. Grant 14-Sep-2007 $187K Completed Pre-Clinical Trials
1. Early Stage VC 22-Nov-2006 Completed Startup
To view Beactica Therapeutics’s complete valuation and funding history, request access »

Beactica Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a drug discovery platform designed to facilitate the treatment of glioblastoma and other cancers. The compa
Drug Discovery
Uppsala, Sweden
16 As of 2022
0000000000

000000

ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
0000 000000000
Oxford, United Kingdom
00 As of 0000
000.00
00.00 0000-00-00
0000000000 0 000.00

00000000

aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea com
0000 000000000
Watertown, MA
00 As of 0000
0000
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Beactica Therapeutics Competitors (77)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sitryx Venture Capital-Backed Oxford, United Kingdom 00 000.00 0000000000 0 000.00
00000000 Venture Capital-Backed Watertown, MA 00 0000 00000000000 0000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
You’re viewing 5 of 77 competitors. Get the full list »

Beactica Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Per Kallblad Ph.D Co-Founder & Chief Executive Officer
Helena Danielson Ph.D Co-Founder, Consultant & Board Member
Jan-Olof Karlsson Head of Finances
You’re viewing 3 of 5 executive team members. Get the full list »

Beactica Therapeutics Board Members (12)

Name Representing Role Since
Christina Herder Ph.D Self Board Member 000 0000
Erik Walldén Self Board Member 000 0000
Hakan Wickholm Self Chairman 000 0000
Helena Danielson Ph.D Beactica Therapeutics Co-Founder, Consultant & Board Member 000 0000
Maarten de Château Ph.D Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Beactica Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Beactica Therapeutics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
SWElife Accelerator/Incubator 000 0000 000000 0
Flerie Invest Venture Capital Minority 000 0000 000000 0
M2Capital PE/Buyout Minority 000 0000 000000 0
Horizon 2020 Government 000 0000 000000 0
Unionen Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial